RasGRP1 is a potential biomarker for stratifying anti-EGFR therapy response in colorectal cancer
Oghenekevwe M. Gbenedio, … , Jeroen P. Roose, Philippe Depeille
CI Insight. 2019;4(15):e127552. https://doi.org/10.1172/jci.insight.127552
Colorectal cancer (CRC) is the third most frequent neoplastic disorder and is a main cause of tumor-related mortality, as many patients progress to stage IV metastatic CRC. Standard care consists of combination chemotherapy (FOLFIRI or FOLFOX). Patients with WT KRAS typing are eligible to receive anti-EGFR therapy combined with chemotherapy.